BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-510@pharmaconomics
DTSTAMP:20260707T033631Z
DTSTART;VALUE=DATE:20250331
DTEND;VALUE=DATE:20250401
SUMMARY:ABOS Phase 1 — sabirnetug (ACU193) (estimated date)
DESCRIPTION:Phase 1 trial results for sabirnetug (ACU193) in Alzheimer's Disease are due ~ Mar 31\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/acumen_ncxcorporatexdeck.htm\n\nTrack it: https://pharmaconomics.com/e/510
URL:https://pharmaconomics.com/e/510
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ABOS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR